Completed PHASE4 INTERVENTIONAL NCT00469183

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma

Sponsor: Galderma R&D

Conditions Melasma

Interventions Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%

Updated 6 times since 2017 Last updated: Jul 28, 2022 Started: May 31, 2006 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Melasma, this trial is completed. The trial is conducted by Galderma R&D and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Sep 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galderma R&D

Data source: Galderma R&D

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States
• Los Angeles, United States